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Regulatory T cells (Tregs) have a fundamental function in monitoring the immune homeostasis in healthy individuals. In cancer
and, in particular, in hematological malignancies, Tregs exert a major immunosuppressive activity, thus playing a critical role in
tumor cell growth, proliferation, and survival. Here, we summarize published data on the prognostic signiﬁcance of Tregs in
hematological malignancies and show that they are highly conﬂicting. The heterogeneity of the experimental approaches that
were used explains—at least in part—the discordant results reported by diﬀerent groups that have investigated the role of Tregs
in cancer. In fact, diﬀerent tissues have been studied (i.e., peripheral blood, bone marrow, and lymph node), applying diﬀerent
methods (i.e., ﬂow cytometry versus immunohistochemistry, whole blood versus isolated peripheral blood mononuclear cells
versus depletion of CD25+ cells, various panels of monoclonal antibodies, techniques of ﬁxation and permeabilization, and
gating strategies). This is of relevance in order to stress the need to apply standardized approaches in the study of Tregs in
hematological malignancies and in cancer in general.
1. Introduction
Regulatory T cells (Tregs) constitute a small-size subpopula-
tion of CD4+ T cells, accounting for 1–4% of circulating
CD4+ lymphocyte in humans, specialized in suppressive
functions that control unwanted immune responses not only
toward self-antigens but also toward foreign antigens in the
context of the immune tolerance [1].
Gershon and Kondo from Yale University ﬁrst proposed
the existence of CD8+ T cells with suppressive activity more
than 40 years ago [2]. However, after the initial great interest
following this ﬁrst report, due to the fact that a precise
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deﬁnition of Tregs lacked for several years, no further
advances in the study of this cell population were made for
decades. In 1995, Sakaguchi and coworkers identiﬁed Tregs
in mouse as CD4+ T cells expressing surface interleukin-2
(IL-2) receptor α-chain (CD25) [3]. Baecher-Allan and
coworkers, using ﬂow cytometry and analyzing sorted cells
in vitro, identiﬁed a very small subset of T cells with high
expression of CD25 and regulatory function in humans [4].
However, CD25 is not exclusively restricted to Tregs, and
its surface expression is also seen on eﬀector T lymphocytes
after activation [5]. The intracytoplasmic Forkhead helix
box P3 (FoxP3), a transcription factor required for the
development, maintenance, and function of Tregs was subse-
quently identiﬁed [6, 7]. The central role of this transcription
factor is conﬁrmed by the fact that a FoxP3 single gene muta-
tion on the X chromosome induces in Scurfy mice a severe
autoimmune/inﬂammatory disease. In humans, the same
mutation causes a disease called IPEX (immune dysregula-
tion, polyendocrinopathy, enteropathy, X-linked syndrome),
characterized by autoimmune manifestations in multiple
endocrine organs, such as diabetes and thyroiditis, inﬂam-
matory bowel disease, and severe allergies [8]. Finally, the
absence of the heterodimeric IL-7 receptor (CD127) com-
bined with CD4, CD25, and FoxP3, has been shown to better
identify Tregs, avoiding the contamination from other cell
populations such as activated eﬀector T cells [9, 10].
2. Regulatory T Cells and Prognostic
Significance in Cancer
The role of Tregs in cancer appears to be relevant by pro-
moting tumor progression and suppressing eﬀective antitu-
mor activity [11–13]. Overall, the large majority of studies
report that the frequency and the suppressive function of
Tregs are increased in cancer patients as compared to
healthy subjects. However, some issues are still a matter of
debate, in particular the prognostic signiﬁcance of this cell
subpopulation. In general, Tregs predict poor outcome in
cancer patients [12], but some reports have shown that
higher Treg numbers and preserved activity are associated
with a better prognosis [14–16].
This review stems from the need to reassess the topic of
prognostic relevance of Tregs in cancer, focusing on patients
with hematologic malignancies. For this purpose, we
reviewed a large body of published papers conducting a
PubMed literature search (keywords: Regulatory T cells,
Hodgkin lymphoma, non-Hodgkin lymphoma, chronic lym-
phocytic leukemia, chronic myeloid leukemia, acute lympho-
blastic leukemia, acute myeloid leukemia, multiple myeloma,
monoclonal gammopathies, myeloﬁbrosis, essential throm-
bocythemia, polycythemia vera, and Ph1-negative chronic
myeloproliferative neoplasms).
3. Regulatory T Cells in Chronic Lymphocytic
Leukemia
The accumulation of monoclonal B lymphocytes in the bone
marrow, lymphoid organs, and peripheral blood is the hall-
mark of chronic lymphocytic leukemia (CLL), the most
common form of leukemia in Western countries [17]. The
importance of T cell dysregulation in the pathogenesis and
development of CLL is now well established [18, 19], and
in this setting, the role of Tregs has also been investigated
[20, 21]. As shown in Table 1, several authors reported data
onTregs inCLL showing in themajority of cases an expansion
of this population [22–31]. In addition, a correlation between
higher Treg numbers and more aggressive clinical-biological
features and adverse prognosis of CLL has been described.
As previously discussed [20], the reported percentage of
Tregs in CLL is highly variable. According to the majority
of reports, the percentage of Tregs is higher in CLL patients
than in normal controls, and when the absolute number is
considered, Tregs are always found to be signiﬁcantly greater
in CLL as compared to healthy donors.
Interestingly, based on their experimental work, Jak et al.
speculated that the accumulation of Tregs in CLL is due to an
increased proliferation induced by CD27/CD70 interaction
in the lymph node proliferation centers and to a decreased
sensitivity to apoptosis [22].
Dasgupta et al. tried to establish an optimal threshold
level for prognostic purpose [28]. The cut-oﬀ was assessed
by receiver operating characteristic (ROC) analysis. A cut-
oﬀ of 5.7% and 35 cells/μL for percentage and absolute Treg
count, respectively, were determined as optimal in patients
with CLL, along with a median Tregs percentage of 15.5%
used to separate low- and high-risk patients. Using the same
approach in the setting of Rai stage 0 CLL patients, our group
found that the absolute number of Tregs was an independent
predictor of time to the ﬁrst treatment, with the best predic-
tive cut-oﬀ being 41 cells/μL [24]. Overall, these data show
that the absolute Treg number is able to identify Rai stage 0
CLL patients at higher risk of requiring therapy.
Rissiek et al., applying a multidimensional scaling anal-
ysis to assess the composition of the circulating T cell pop-
ulations, generated T cell scores showing that suppressive
T cell proﬁles emerge early during monoclonal B cell
lymphocytosis (MBL), the well-recognized pre-CLL stage
[31–33]. As the disease evolves from MBL to overt and
advanced CLL, speciﬁc sequential changes in T cells appear,
progressively compromising the eﬀector T cells function
and contributing to disease progression [30].
In our hands too, the absolute number of Tregs in MBL
patients was lower compared to CLL patients, but slightly
higher than healthy controls [30]. In addition, the absolute
Treg cell number directly correlated with more advanced
CLL clinical stages and higher circulating B cell numbers.
Of note, the absolute number of Tregs was lower in MBL
patients as compared to early-stage CLL patients (0/A
according to Rai/Binet stage). In summary, Treg numbers
increase gradually from normal subjects to “clinical” MBL
patients and are signiﬁcantly higher in CLL patients as
compared to MBL patients.
Regarding the functional properties, some authors
reported a reduced inhibitory function of Tregs in CLL
[27, 34]. On the contrary, Piper et al. showed that in
CLL patients Tregs retain their function and are not inﬂu-
enced by chemotherapy [35]. A correlation between a higher
circulating Treg numbers and dysfunctional Vγ9Vδ2 T cells
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in untreated CLL patients was also shown, thus corroborating
the hypothesis that Tregsmay not be only bystanders but have
a functional role in this setting [36].
A normalization in Treg number was observed after
ﬂudarabine therapy [34], and also in CLL patients treated
with lenalidomide, suggesting that such drugs are able to
modulate cell-mediated immunity in CLL [37].
Finally, we also tested the ability of green tea, a popular
beverage in China, Japan, and increasingly used in Western
countries, to modulate Treg number in peripheral blood of
CLL patients in the early phases of the disease, for which at
the present time there is no eﬀective intervention and a “wait
and see” policy is generally adopted [38, 39]. We showed that
the B cell lymphocyte count and the absolute circulating Treg
number were reduced after 6-month consumption of oral
green tea extract, suggesting that this compound can modu-
late circulating Tregs in CLL patients with early stage of
disease and delay disease progression.
4. Regulatory T Cells in Lymphomas and
Monoclonal Gammopathies
The neoplastic lymph nodes in Hodgkin lymphoma (HL)
and non-Hodgkin lymphoma (NHL) contain not only neo-
plastic B cells but also nontumoral T cells, macrophages,
and dendritic cells, constituting the so-called tumor microen-
vironment. The importance of the microenvironment in the
pathogenesis and progression of lymphomas is still a matter
of debate and many studies have focused on the role of its
diﬀerent components, including Tregs. Tregs are increased
in lymphoma tissues and are able to inhibit cytotoxic CD8+
T cells exposed to lymphoma B cells [40].
Marshall et al. showed that HL-inﬁltrating lymphocytes
are highly enriched in Tregs, which induce a profoundly
immunosuppressive environment [41]. This was conﬁrmed
by Schreck et al. who demonstrated that in classical HL the
microenvironment is dominated by Th2 cells and Tregs
[42]. Moreover, a high ratio of Tregs over Th2 cells resulted
in a signiﬁcantly shortened disease-free survival.
However, conﬂicting results have been reported regard-
ing the prognostic signiﬁcance of Tregs inﬁltration in both
HL and NHL. In fact, whereas in follicular lymphoma (FL),
the most common form of low-grade NHL, germinal center
(GC) diﬀuse large B cell lymphomas (DLBCL), and HL, an
intrafollicular inﬁltration of Tregs, has a positive prognostic
signiﬁcance; this is not true in the case of non-GC-type
DLBCL [43]. Moreover, as shown in Table 2, in some reports,
a higher number of Tregs correlates with a good prognosis,
while in other, it does not [43–49]. Of interest, Kim et al.
evaluating Tregs on node biopsy of extranodal natural
killer/T cell lymphomas showed that patients with poor
performance status and with non-upper aerodigestive tract
had a decreased number of Tregs (<50/0.40mm2), while an
increased number (>50/0.40mm2) was associated with
prolonged overall survival and progression-free survival
[48]. Finally, Carreras et al. reported that the median Treg
number in patients with FL at diagnosis had a median cell
percentage of 10.5% [49]. Furthermore, patients were classi-
ﬁed as having Tregs> 10%, 5–10%, and <5% with a 5-year
overall survival of 80%, 74%, and 50%, respectively. Patients
with transformed DLBCL showed lower Treg number with
respect to patients with grades 1–3 FL.
Regarding the frequency and prognostic signiﬁcance of
Tregs, conﬂicting results have also been obtained in the ﬁeld
of monoclonal gammopathies (Table 3). In some reports,
Tregs were found to be increased in frequency, while in others
they were reduced or comparable with respect to healthy sub-
jects [50]. Again, some authors reported a correlation with
tumour burden and with worse prognosis, but this was not
consistent among diﬀerent publications [50–57]. We recently
published our data on the ﬂow cytometric evaluation of Tregs
in multiple myeloma (MM) and monoclonal gammopathies
of undetermined signiﬁcance (MGUS) [51].We found no dif-
ferences in Treg frequency in MM andMGUS with respect to
normal controls, and no correlations with main clinical and
laboratory features in this disease setting were observed.
5. Regulatory T Cells in Acute Leukemias,
Chronic Myeloid Leukemia, and
Ph1-Negative Chronic Myeloproliferative
Neoplasms
Few studies have been published regarding the role of Tregs
in acute myeloid and lymphoid leukemias (Table 4) [58–61].
In a study by Bhattacharya et al., an increased number of
Tregs was found in patients with B cell acute lymphoblastic
leukemia (B-ALL), and a correlation with disease progres-
sion was highlighted [58].
Regarding chronic myeloid leukemia (CML), an interest-
ing paper has been published by Zahran and Badrawy, in
which Tregs were found increased in the peripheral blood
of aﬀected individuals as compared to controls. Moreover,
Tregs frequency correlated with the level of BCR/ABL,
basophil number, blast cell count, and Sokal score, and Treg
number was higher in accelerated and blastic phase with
respect to chronic phase [62]. Of note, Treg frequency
declined after therapy with imatinib. Rojas et al. found a
lower Treg number in patients who achieved a complete
cytogenetic response [63], while higher Treg frequencies
were found after stem cell transplant compared to normal
controls and newly diagnosed patients [64]. Finally, the
correlations with Sokal score and basophil number were
validated by other studies [65, 66], whereas the impact of
treatment has not been conﬁrmed, since no changes in Treg
frequency was observed after 6 months of tyrosine kinase
inhibitors therapy [65]. Table 5 summarizes the results of
studies analyzing Tregs in CML.
Hasselbalch et al. studied patients with Ph1-negative
chronic myeloproliferative neoplasms and found that circu-
lating Tregs were signiﬁcantly expanded in patients treated
with IFN-α2 with respect to healthy donors and in patients
treated with hydroxyurea [66]. Kovacsovics-Bankowski et al.
analyzed patients with polycythemia vera (PV) and essential
thrombocythemia (ET) and found increased numbers of
circulating Tregs and an enrichment in highly suppressive
subsets (deﬁned asCD39+/HLA-DR+) in patients treatedwith
PegIFN-αwith respect to those treatedwith hydroxyurea [67].
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Moreover, molecular nonresponder patients showed a trend
towards increased frequency of Tregs compared to responder
patients, but no changes were observed in terms of absolute
numbers of Tregs. Overall, a positive correlation between pro-
liferating Tregs (Ki-67+), highly suppressive Tregs (CD39+/
HLA-DR+), and JAK2V617F allelic burden was found, thus
suggesting that the lack of ability of PegIFN-α treatment to
decrease circulating Tregs predicts a poormolecular response.
Primary myeloﬁbrosis (PMF) is a clonal disease of the
hematopoietic stem cell characterized by a variable degree
of bone marrow ﬁbrosis, splenomegaly, and an increased risk
of leukemic transformation. Contradictory data about Tregs
in PMF have been published (Table 6). Massa et al. reported
a reduced frequency and absolute number of Tregs in PMF
than in normal controls [68]. No association with clinical-
biological features of the disease was found, but a correlation
between reduced Treg frequency and longer disease duration
in patients with CALR mutation genotype was described. In
these patients, a higher Treg frequency is signiﬁcantly associ-
ated with advanced disease, higher IPSS/DIPSS score, and
lower hemoglobin concentration. The same authors later
documented the eﬀect of ruxolitinib on Treg frequency,
showing that the treatment with this small-molecule JAK1/2
inhibitor leads to a profound and long-lasting reduction in
the frequency of circulating Tregs [69]. Wang et al. found
no signiﬁcant diﬀerences in the number of Tregs in patients
with primary or post-ET myeloﬁbrosis [70]. However, they
reported that ruxolitinib signiﬁcantly inhibits the release of
sIL2-Rα, an inﬂammatory cytokine produced by Tregs,
contributing to the clinical improvement of constitutional
symptoms induced by the drug. These data have been
further conﬁrmed by an in vitro study in which the JAK1/2
inhibition by ruxolitinib was able to prevent Treg diﬀerentia-
tion [71]. Table 6 summarizes the results of studies analyzing
Tregs in Ph1-negative chronic myeloproliferative neoplasms.
6. Conclusions
Tregs have a fundamental function in maintaining the
immune homeostasis in healthy individuals. In cancer and
in particular in hematological malignancies, Tregs exert a
major immunosuppressive activity, thus playing a critical
role in tumor cell growth, proliferation, and survival. Pub-
lished data on the prognostic signiﬁcance of the Treg number
in hematological malignancies show conﬂicting results. In
our opinion, this variability reported by diﬀerent groups is
most likely explained by the heterogeneity of the experimental
approaches that are used. In fact, diﬀerent tissues have been
studied (i.e., peripheral blood, bone marrow, and lymph
node) and diﬀerent analytic methodologies have been applied
(i.e., ﬂow cytometry versus immunohistochemistry). More-
over, while some authors studied the whole blood compart-
ment, others evaluated the Treg population in isolated
peripheral blood mononuclear cells or in a CD25-depleted
subpopulation. Finally, various panels of markers, diﬀerent
techniques of ﬁxation and permeabilization, and several gat-
ing strategies have been applied. This is of relevance to stress
the need to apply standardized approaches in the study of
Tregs in hematological malignancies and in cancer in general.
In perspective, in light of the increasing evidence of the
important role of Tregs in immune evasion mechanism
exerted by tumor cells, therapeutic interventions targeting
intratumoral Treg inﬁltrates may be conceived in order to
ﬁght cancer. Treg inhibition or depletion, the latter uses
monoclonal antibodies targeting surface antigens on Tregs
such as CD25, is currently under investigation [72].
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